To include your compound in the COVID-19 Resource Center, submit it here.

Taking RNA epigenetics by Storm

Storm is tapping the nascent field of RNA epigenetics for cancer

Storm Therapeutics Ltd. is the first company to come out of the budding field of RNA epigenetics, and is targeting RNA-modifying enzymes for cancer.

CEO Keith Blundy told BioCentury RNA-modifying enzymes fit into the landscape of epigenetic targets because, like DNA-modifying enzymes, they alter gene expression without changing the genetic code.

"It's the same paradigm as DNA and histone modification enzymes that have

Read the full 624 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE